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Edited by Varda RotterAbstract Jab1 overexpression is observed in many human can-
cers, but its physiological signiﬁcance remains to be investigated.
We reduced the level of Jab1 expression in pancreatic cancer cell
lines, MIA PaCa-2 and PANC-1 by the RNA interference and
found that Jab1-knockdown resulted in impaired cell prolifera-
tion and enhanced apoptosis regardless of the genotype of the
tumor suppressor p53. This growth inhibition was rescued by
the introduction of siRNA-resistant mouse Jab1 cDNA. Jab1-
knocked-down cells expressed a higher level of c-myc, and
additional depletion of c-myc rescued cells from Jab1-knock-
down-mediated growth suppression. Thus, Jab1 overexpression
contributes to pancreatic cancer cell proliferation and survival.
Jab1 could be a novel target in cancer therapy.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis; Myc1. Introduction
Pancreatic cancer represents one of the most lethal malig-
nancies [1]. In most cases, the tumors are very advanced at
the time of diagnosis and usually unresectable [2,3]. Further-
more, the tumor cells are unusually resistant to chemotherapy
and radiation therapy. Recently, the genes involved in pancre-
atic ductal adenocarcinoma were identiﬁed, including K-ras,
p16INK4a, p53, and Smad4 [4], and a mouse model recapitulat-
ing the development of the human malignancy was developed,
in which activation of K-ras and inactivation of p53 cooperate
to promote pancreatic cancer [5]. However, to deﬁne the
genetic basis of molecular targets for better pancreatic cancer
therapy, the identiﬁcation and characterization of the novel
genes involved in pancreatic carcinogenesis are needed.
We previously found that the Jab1 is overexpressed in pan-
creatic cancer cells [6]. Jab1 interacts with and controls multi-
ple intracellular signaling molecules such as c-Jun, p27,
HIF1a, Smad4, p53, and CUL1 (SCF) in mammalian cells
[7,8]. Jab1 is identical to the ﬁfth component (CSN5) of the
COP9 signalosome complex (CSN), which is well conserved
from yeast to human, and involved in a variety of biological
responses such as development, oogenesis, immune response,*Corresponding author. Fax: +81 743 72 5519.
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and cell cycle control in various organisms [8–11]. The CSN
core is composed of eight subunits (CSN1-8) [12], locates in
the nucleus, and associates with diﬀerent types of enzymes; ki-
nases, ligases, and a de-ubiquitinating enzyme. CSN-associ-
ated kinases are capable of phosphorylating c-Jun, NFjB,
and p53 in vitro [12]. In proliferating mammalian cells, inhibi-
tion of CSN-associated kinases results in accumulation of p53
and eventual cell cycle arrest/apoptosis, indicating that phos-
phorylation of p53 by CSN-associated kinases destabilizes
the p53 protein [13]. CSN interacts with the cullin subunit of
ubiquitin ligases, which controls diverse biological processes
by regulating the stability of key regulatory proteins, and cat-
alyzes the reaction to remove a ubiquitin-like polypeptide,
Nedd8, from the cullin subunit (deneddylation) [14,15], there-
by regulating the ligase activity [16,17]. The JAMM domain
within the Jab1 (CSN5) subunit plays an essential role in this
reaction [15]. As well as a component of the CSN complex,
Jab1 was found as a small complex [18–22]. The physiological
signiﬁcance of the smaller form and the relationship to the
CSN complex remain to be determined.
During development, the level of Jab1 expression is mark-
edly higher in embryos, where vigorous cell proliferation oc-
curs, than in adult mice [23]. Jab1 gene-knockout in mice
results in embryonic lethality largely due to impaired prolifer-
ation of embryonic cells [24]. These results indicate that Jab1
plays an essential role in cell growth and strong expression
of Jab1 is connected with accelerated proliferation. In fact, a
high level of Jab1 is observed in a variety of human cancer
[25–35] including pancreatic cancer [6]. However, the physio-
logical signiﬁcance of Jab1 overexpression in cancer cells and
the molecular mechanism by which Jab1 is involved in human
cancer development remain to be examined. In this study, we
chose two pancreatic cancer cell lines, MIA PaCa-2 and
PANC-1, and analyzed the eﬀect of Jab1-knockdown on their
survival and proliferation. We found that Jab1-depletion re-
sulted in inhibition of cell proliferation via enhanced apopto-
sis, which is independent of the p53 gene status.2. Materials and methods
2.1. Cell culture, siRNA transfection and cell proliferation analyses
The cell lines used in this study were maintained in Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM) containing 100 U/ml of penicillin,
100 lg/ml of streptomycin, and 10% fetal bovine serum (FBS). The
vectors for RNA interference (RNAi) speciﬁc to the mouse and human
Jab1 were described previously [36]. Other RNAi vectors were con-
structed based upon the pSilencer expression vector system (Ambion)blished by Elsevier B.V. All rights reserved.
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gos; human cyclin E (cycE) RNAi sense (5 0-GTG CTA CTG CCG
CAG TAT CTT CAA GAG AGA TAC TGC GGC AGT AGC
ACT TTT TT-3 0), cycE RNAi anti-sense (5 0-AAT TAA AAA AGT
GCT ACT GCC GCA GTA TCT CTC TTG AAG ATA CTG
CGG CAG TAG CAC GGC C-3 0), human c-myc (myc) RNAi sense
(5 0-GCC ACA GCA TAC ATC CTG TTT CAA GAG AAC AGG
ATG TAT GCT GTG GCT TTT TT-3 0), and myc RNAi anti-sense
(5 0- AAT TAA AAA AGC CAC AGC ATA CAT CCT GTT CTC
TTG AAA CAG GAT GTA TGC TGT GGC GGC C-3 0). Mouse
Jab1 mutants harboring point mutations in the MPN domain [15]
and in the NES motif [21] were generated by PCR. Cells were transfec-
ted with expression vectors by a modiﬁed calcium phosphate-DNA
precipitation method [37].
For the growth curve assay, cells transfected with a pMSCVpur-
oGFP marker plasmid together with siRNA expression vectors (ratio
of 1:10) were selected in the presence of puromycin (5 lg/ml, Clontech)
for 1 day and enumerated every day. For the colony formation assay,
cells transfected with a neo marker plasmid together with siRNA
expression vectors (ratio of 1:10) were selected in the presence of
G418 (1 mg/ml, Geneticin, GIBCO) for 2–4 weeks (2 weeks for MIA
PaCa-2, 3 weeks for PANC-1, and 4 weeks for MCF7 and HeLa cells),
ﬁxed in 4% paraformaldehyde, and stained in 0.4% crystal violet. Only
colonies bigger than 1 mm in diameter were counted. The ﬂow cyto-
metric analysis of DNA content was described previously[21].
2.2. Immunostaining and protein analyses
Immunoﬂuorescent staining, incorporation of BrdU, cell lysis, SDS–
polyacrylamide gel electrophoresis, immunoblotting, glycerol gradient
centrifugation and non-denaturing gel electrophoresis were performed
as described [21,22,24,36]. The assay of apoptosis (TUNEL assay) was
performed according to the manufacture’s instructions (ApopTag Red,
Intergen).
2.3. Antibodies
A rabbit polyclonal antibody speciﬁcally recognizing mouse Skp2
was produced against 6·His-tagged full-length polypeptides expressed
in bacteria. The generation of antibodies to CSN subunits was de-
scribed previously [21]. Rabbit polyclonal antibodies to Cdk2 (M2),
p21 (C-19), p27 (C-19), cyclin A (C-19), and Bcl2 (DC21), and mouse
monoclonal antibodies to p53 (DO-1), cyclin E (HE12), and c-Myc
(9E10) were purchased from Santa Cruz Biotechnology. Mouse
monoclonal antibodies to mouse p27 (clone 57) and Bcl-xl (44) were
obtained from Transduction Laboratories. Mouse monoclonal anti-
bodies to c-tubulin (GTU-88) and an HA peptide epitope (12CA5)
were from Sigma. Rabbit polyclonal antibodies to Cul1 (ZL18) and
GFP (Living Colors) were purchased from Zymed and Clontech,
respectively. Mouse monoclonal antibodies to retinoblastoma protein
(XZ91, G3-245) were obtained from Pharmingen.3. Results
3.1. SiRNA-mediated depletion of Jab1 inhibits the proliferation
of pancreatic cancer cell lines
To investigate the function of Jab1 in human cancer cells, we
used the RNA interference technique to speciﬁcally deplete the
Jab1 protein in the pancreatic cancer cell line MIA PaCa-2.
When we introduced a small interfering RNA (siRNA) expres-
sion vector speciﬁc to human Jab1 (hJab1-siRNA) into MIA
PaCa-2 cells together with a marker plasmid containing GFP
and puromycin-resistance genes by the calcium-phosphate pre-
cipitation technique, most of the Jab1 protein disappeared
from the nucleus and the cytoplasm of the transfected cells
(Fig. 1A). Importantly, the downregulation of Jab1 occurred
only in the cells that successfully took up the plasmids (visual-
ized by the GFP marker protein). The eﬀect of the Jab1-spe-
ciﬁc knockdown was evident at 48 h after transfection
(Fig. 1A, upper panels) and sustained thereafter (for example,
see the cells at 72 h after transfection in Fig. 1A, lower panels,and western blots using the 168 h samples in Fig. 1B). The
SDS–PAGE immunoblotting method showed that the total
amount of Jab1 protein decreased by 70–80% in these transfec-
ted cells and, furthermore, the native-PAGE fractionation
method, which has been shown to be very eﬀective in separat-
ing the diﬀerent Jab1-containing complexes (the COP9 signalo-
some (CSN) complex and the small Jab1 complex) [22,36]
revealed that, in hJab1-siRNA-transfected cells, the amount
of the CSN complex as well as the small Jab1 complex was re-
duced (more eﬀective for CSN than the small complex)
(Fig. 1B). The result is consistent with the previous report that
removal of one CSN subunit brings the whole CSN complex
unstable and downregulates other subunits. In fact, other sub-
units of the CSN complex (CSN3 and CSN8) were downregu-
lated in RNAi vector-transfected MIA PaCa-2 cells (Fig. 1B).
The siRNA vector designed according to the mouse Jab1 se-
quence (mJab1-siRNA) did not alter the expression level of
the human protein, indicating that the eﬀect of the siRNA is
highly speciﬁc, and precluding the possibility of a non-speciﬁc
downregulation of the protein expression caused by the ‘‘inter-
feron response’’.
To examine the eﬀect of the depletion of Jab1 on cell growth,
we plated the transfected cells after selection in puromycin at a
low cell density (1 · 105 cells/60 mm dish), and counted
them everyday. The growth curve analysis showed that Jab1-
depleted cells grew signiﬁcantly slower than negative control
(luciferase and mouse Jab1) siRNA-transfected cells
(Fig. 1C). Using an alternative approach, we transfected cells
with siRNA vectors together with a marker plasmid containing
a neomycin-resistance gene, and enumerated the colonies that
appeared after selection in the presence of G418 for 2 weeks.
The introduction of hJab1-siRNA generated a signiﬁcantly
smaller number of colonies than transfection with mJab1-siR-
NA (14.9 ± 3.38 versus 100, Fig. 1D), consistent with the re-
sults of the growth curve analysis. To examine whether this
is speciﬁc to the MIA PaCa-2 cell line, we used another pancre-
atic cancer cell line, PANC-1, and obtained a similar result
that transfection with hJab1-siRNA resulted in poorer colony
formation than transfection with control mJab1-siRNA
(30.1 ± 15.2 versus 100, Fig. 1E). Thus, we conclude that
Jab1 depletion by speciﬁc siRNA results in inhibition of cell
proliferation in human pancreatic cancer cell lines. In addition,
it should be mentioned that MIA PaCa-2 cells contain the mu-
tant allele of the tumor suppressor gene p53, indicating that
growth suppression mediated by Jab1-depletion does not de-
pend on the intact p53 loci.3.2. Jab1-depletion does not induce G1 arrest in the cell cycle but
accelerates apoptotic cell death
In order to ﬁnd how Jab1-depletion inhibited the growth of
pancreatic cancer cells, we examined the eﬀect of hJab1-siRNA
treatment on the cell cycle. At 168 h after transfection of
hJab1-siRNA, MIA PaCa-2 cells were harvested and the cell
cycle distribution was analyzed by FACS. Cells treated with
control mJab1-siRNA contained 54% G1-phase, 32% S-phase,
and 14% G2/M-phase populations (Fig. 2A, upper panel),
whereas hJab1-siRNA treatment decreased the G1 population
by 11% with a compensatory increase in S and G2/M phases by
6% and 5%, respectively (Fig. 2A, lower panel). BrdU incorpo-
ration was also enhanced by 7% in hJab1-siRNA-treated cells
(Fig. 2A), indicating that the cells were in cycle and this does
Fig. 1. Speciﬁc Jab1-depletion by siRNA inhibits the proliferation of human pancreatic cancer cell lines. (A) Speciﬁc Jab1-depletion in siRNA-
transfected cells. MIA PaCa-2 cells were transfected with a human Jab1-siRNA expression vector and a GFP marker vector (ratio of 10:1). After 48
(48H) and 72 (72H) hours, cells were ﬁxed and immunostained using antibody to Jab1 (Jab1). The GFP signals are also shown (GFP). PC, phase-
contrast. GFP-positive cells are marked by arrowheads. For a control, non-transfected cells (NT) are shown. (B) Immunoblot analysis of siRNA-
transfected cells. MIA PaCa-2 cells were transfected with control (Luciferase), mouse Jab1 (mJab1), and human Jab1 (hJab1) siRNA vectors, and
harvested after 168 h. Cell lysates were separated by native PAGE (COP9 complex and small complex) and SDS–PAGE (lower four rows) and
analyzed by immunoblotting using antibodies to Jab1, CSN3, CSN8, and c-tubulin. (C) Growth curve analysis of siRNA-transfected cells. MIA
PaCa-2 cells were transfected with control (Luciferase), mouse Jab1 (mJab1), and human Jab1 (hJab1) siRNA vectors together with a puromycin
resistant marker plasmid (ratio of 10:1) and selected in the presence of puromycin (5 lg/ml) for 1 day. Living cells were plated at 1 · 105 cells per 6 cm
dish and counted everyday. Data shown are means ± S.D. (D, E) Colony formation assay of siRNA-transfected cells. MIA PaCa-2 (D) and PANC-1
(E) cells were transfected with control (mouse Jab1 and mJab1) and human Jab1 (hJab1) siRNA vectors together with a neo marker plasmid (ratio of
10:1) and selected in the presence of G418 (1 mg/ml) for 2 (D) and 3 (E) weeks. The colonies were stained in 0.4% crystal violet (upper panels). Only
colonies with a diameter >1 mm were counted (lower). Data shown are means ± S.D. *P = 0.0005 (D) and 0.0125 (E), respectively. Mock means
transfection without plasmid DNAs.
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delay in S/G2/M progression. To seek for the other possibility
to explain the paradox that Jab1-depleted cells were cycling
though they grew very poorly (see Fig. 1C), we examined
whether apoptotic cell death was accelerated in these cells.TUNEL analysis revealed that hJab1-siRNA-treatment in-
creased the population of apoptotic cells from 1.85 ± 0.78%
to 9.75 ± 6.29% (Fig. 2B). During the assay, we observed a
substantial number of ﬂoating cells in hJab1-siRNA-transfec-
ted populations, consistent with the idea that Jab1-depletion
Fig. 2. Speciﬁc Jab1-depletion in pancreatic cancer cells does not induce cell cycle arrest in G1, but accelerates apoptosis. (A) Cell cycle analysis of
siRNA-transfected cells. MIA PaCa-2 cells were transfected with control (mouse Jab1 and mJab1) and human Jab1 (hJab1) siRNA vectors together
with a puromycin resistance marker plasmid (ratio of 10:1) and selected in the presence of puromycin (5 lg/ml) for 1 day. At 168 h post-transfection,
cells were subjected to a ﬂow cytometric analysis of DNA content and a BrdU incorporation assay. More than 500 BrdU-stained cells were
enumerated. (B) Enhanced apoptosis in Jab1-depleted cells. MIA PaCa-2 cells were transfected and selected as in panel A. At 168 h post-transfection,
cells were viewed by phase contrast (PC), or ﬂuorescence microscopy after being stained with Hoechst dye (DNA) and subjected to a TUNEL assay
(TUNEL) (upper panels). More than 500 cells were enumerated for each sample (lower). Data shown are means ± S.D. *P = 0.0006.
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number of cells undergoing apoptosis was underestimated in
this assay.
It seems worth while pointing out that the cell cycle distribu-
tion was analyzed for cells remained on the plate. Therefore, it
is important to carefully interpret the results that Jab1-de-
pleted cells were still in cycle. Cells could be dying while pro-
gressing through the cell cycle, or, alternatively, cells may
undergo apoptosis exclusively from G1 (so that the G1 popu-
lation is selectively reduced).
3.3. Jab1-depletion induces growth inhibition in non-pancreatic
cell lines
To examine whether growth inhibition mediated by Jab1-
depletion is speciﬁc to pancreatic cancer cells, we investigated
the eﬀect of hJab1-siRNA on other cancer cell lines; the breast
cancer cell line MCF7 and the cervical cancer cell line HeLa.
Colony formation assays, in which cells were subjected to
transfection with an siRNA vector and a marker plasmid con-
taining a neomycin-resistance gene followed by selection in the
presence of G418 for 4 weeks, showed that transfection with
luciferase siRNA and mJab1-siRNA did not signiﬁcantly alter
the number of colonies, whereas the introduction of hJab1-
siRNA generated a substantially reduced number of colonies
(Fig. 3A). As a matter of fact, hJab1-siRNA was more eﬀective
in MCF7 and HeLa cells than pancreatic cancer cell lines.
FACS-mediated cell cycle analysis showed that, as in pancre-atic cancer cells, treatment with hJab1-siRNA, but not with
mJab1-siRNA or luciferase siRNA, reduced the population
of cells in G1 phase (ca. 20%) with a compensatory increase
in the population of cells in S and G2/M (Fig. 3B), and consis-
tent with this, BrdU incorporation was also enhanced (data
not shown). Furthermore, the TUNEL assay demonstrated
that hJab1-siRNA-treatment increased the percentages of
apoptotic cells; from 3.80 ± 0.42% to 8.95 ± 0.21% for
MCF7 cells, and from 7.85 ± 2.76% to 24.5 ± 0.49% for HeLa
cells (Fig. 3C). Again, because dead cells were detached from
the plate, the increase in apoptosis was underestimated in
Fig. 3C. Thus, the growth inhibition induced by Jab1 depletion
is not restricted to pancreatic cancer cell lines, but can be in-
duced in other human cancer cells. Considering that MCF7
cells contain the wild-type p53 allele whereas p53 protein is
functionally inactivated in HeLa cells, growth suppression
mediated by Jab1-depletion did not correlate with the status
of the p53 locus.
3.4. Ectopic expression of mouse Jab1 rescues growth
suppression induced by human Jab1-depletion
To conﬁrm the result that the eﬀect of hJab1-siRNA is due
to a speciﬁc depletion of Jab1 protein, we examined whether
ectopic expression of mouse Jab1 protein, which is refractory
to the action of human speciﬁc siRNA, can rescue the growth
suppressive eﬀect of hJab1-siRNA in human cancer cells. MIA
PaCa-2 cells were transfected with siRNA and an HA-tagged
Fig. 3. Jab1-depletion inhibits growth of non-pancreatic cells. (A) Jab1-depletion inhibits colony formation of MCF7 and HeLa cells. Cells were
transfected with no plasmid (Mock), control (Luciferase), mouse Jab1 (mJab1), and human Jab1 (hJab1) siRNA vectors together with a neo marker
plasmid (ratio of 10:1) and selected in the presence of G418 (1 mg/ml) for 4 weeks. After staining in 0.4% crystal violet (the representative result in
MCF7 cells is shown in the upper panel.), only colonies with a diameter >1 mm were counted (lower panel). Data shown are means ± S.D.
*P = 0.0077 (MCF7) and <0.0001 (HeLa), respectively. (B) Cell cycle analysis of siRNA-transfected non-pancreatic cells. HeLa cells were transfected
and selected as in Fig. 3A. At 168 h post-transfection, cells were subjected to ﬂow cytometric analysis of DNA content. (C) TUNEL assay of siRNA-
transfected MCF7 and HeLa cells. Cells were transfected, selected, and subjected to a TUNEL assay as in B. More than 500 cells were enumerated
for each sample (lower). Data shown are means ± S.D. *P < 0.0001 (for both MCF7 and HeLa).
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neomycin-resistance gene. Fig. 4A shows that an equal amount
of HA-tagged mouse Jab1 protein was present in a pool of cells
transfected with control and hJab1-speciﬁc siRNA (compare
2nd and 4th lanes). Importantly, ectopic expression of mouse
Jab1 protein did not alter the level of endogenous human
Jab1 protein with (3rd and 4th lanes) and without hJab1-siR-
NA treatment (1st and 2nd lanes). Transfected cells were al-
lowed to form colonies in the presence of G418 (Fig. 4B),
and the colonies were enumerated after 2 weeks’ selection
(Fig. 4C). Expression of HA-tagged Jab1 protein slightly re-
duced the eﬃciency of colony formation (78.5 ± 2.05%,
P = 0.0946), whereas the introduction of hJab1-siRNA eﬀec-
tively inhibited the cell growth (14.8 ± 3.46%, P = 0.0098).
Interestingly, co-transfection of HA-tagged Jab1 partially
rescued the inhibition of colony formation mediated by
hJab1-siRNA (ca. 2.3-fold increase; 14.8 ± 3.46% versus
34.1 ± 1.20%). These results indicate that the growth inhibition
induced by hJab1-siRNA is truly due to a speciﬁc depletion of
Jab1 protein and not mediated by the accidental depletion of
other proteins by a non-speciﬁc eﬀect of the ‘‘interferon re-
sponse’’, and also show that mouse protein can rescue human
protein deﬁciency.
3.5. An intact JAMM domain is required to rescue the growth
inhibition mediated by Jab1-depletion
To investigate which domain in the Jab1 protein is essential
for tumor cell growth, we constructed expression vectors that
express wild-type and mutant Jab1 protein fused to GFP pro-
tein, and used them for the rescue experiment (Fig. 4D–F).
Jab1 contains the His-X-His-X10-Asp metalloprotease motifthat functions as a catalytic site for the isopeptidase activity
of NEDD8 [15], and the JAMM mutant (DJAMM) harbors
a single amino acid substitution from the conserved Asp to
Asn at codon 151 (D151N). The NES mutant (DNES) contains
three substitutions (L237A, L240A, and L241A) within the
putative NES motif [21]. Introduction of the GFP-fused
wild-type mouse Jab1 into the hJab1-siRNA-treated MIA
PaCa-2 cells rescued the cells from growth suppression, sug-
gesting that fusion with GFP did not abrogate the function
of Jab1. Transfection of the NES mutant signiﬁcantly in-
creased the level of colony forming eﬃciency in these pancre-
atic cancer cells, whereas the JAMM mutant exhibited no
such eﬀect, indicating that the intact JAMM domain, but
not the NES motif, plays an important role in the proliferation
and survival of pancreatic cancer cells.
3.6. A group of cell cycle regulators are upregulated
in Jab1-depleted cancer cells
To obtain an insight into the molecular mechanism of
growth suppression mediated by Jab1-depletion, we investi-
gated the expression of various cell cycle and survival regula-
tors in siRNA-treated cells. MIA PaCa-2 cells were
transfected with hJab1-siRNA, selected in the presence of
puromycin, and harvested at 168 h post-transfection. The cell
lysates were analyzed by immunoblotting using speciﬁc anti-
bodies (Fig. 5). The treatment with mJab1-siRNA did not alter
the expression of any of these regulators, again indicating that
the eﬀect of siRNA is highly speciﬁc and not due to the non-
speciﬁc eﬀect of short RNA. Transfection with hJab1-siRNA
altered the expression levels of several cell cycle and cell sur-
vival regulators. Although the total level of Rb was not chan-
Fig. 4. The eﬀect of human Jab1-depletion is reversed by ectopic expression of mouse Jab1. (A–C) MIA PaCa-2 cells were transfected with siRNA
and an HA-tagged expression vector together with a marker plasmid containing a neomycin-resistance gene. (A) Cells were harvested after 168 h and
the cell lysates were analyzed by immunoblotting using antibodies to Jab1 and CDK2. (B) Cells were selected in the presence of G418 (1 mg/ml) for 2
weeks and stained in 0.4% crystal violet. (a) no plasmid; (b) an empty HA vector and a Luciferase-siRNA vector; (c) an HA-mouse Jab1 vector and a
Luciferase-siRNA vector, (d) an empty HA vector and a human Jab1-siRNA vector, and (e): an HA-mouse Jab1 vector and a human Jab1-siRNA
vector. (C) Only colonies with a diameter >1 mm were enumerated. Data shown are means ± S.D. #P = 0.0946 and *P = 0.0098. (D–F) Recovery of
growth inhibition by ectopic Jab1 requires integrity of the JAMM domain. MIA PaCa-2 cells were transfected with siRNA and an GFP-tagged
expression vector together with a marker plasmid containing a neomycin-resistance gene and subjected to immunoblotting analysis (D) and colony
formation assay (E, F). The combination of vectors used in panel E is shown in panel F. Mock means transfection without plasmid DNAs.
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Cdk inhibitors p27 and p21, c-myc and Bcl-XL were upregu-
lated. The level of increase varied from one protein to another.
The level of Bcl-XL upregulation was subtle and does not seem
to be suﬃcient to suppress apoptosis mediated by Jab1 deple-
tion. Because Jab1 plays a central role in CSN-mediated den-
eddylation of the Cul1 subunit and subsequent regulation of
the SCF (Skp1-Cullin-F box protein) ubiquitin ligase [14,15],
we examined the neddylation status of Cul1 protein in siR-
NA-treated cells. Unexpectedly, the amount of neddylated
Cul1 subunit was not substantially altered by the hJab1-siR-NA treatment. Interestingly, however, we found that the
expression of Skp2 was downregulated in these cells. At the
moment, we do not know the mechanism or the physiological
relevance of this downregulation, but this ﬁnding might partly
explain the phenotype of Jab1-depletion.
3.7. Suppression of c-Myc rescues growth inhibition mediated
by Jab1-depletion
Among the regulatory factors whose expression is upregu-
lated in hJab1-siRNA-treated cells (Fig. 6), we focused our
attention on c-myc, which is potentially involved in the
Fig. 5. Immunoblot analysis of siRNA-transfected cells. MIA PaCa-2
cells were transfected with control (Luciferase), mouse Jab1 (mJab1),
and human Jab1 (hJab1) siRNA vectors, selected in the presence of
puromycin and harvested after 168 h. Cell lysates were analyzed by
immunoblotting using antibodies shown on the left of each panel. Bcl2
was not detected under the conditions used in this experiment.
Fig. 6. Suppression of c-Myc rescues growth inhibition mediated by
Jab1-depletion. MIA PaCa-2 cells were transfected with siRNA
vectors together with a marker plasmid containing a neomycin-
resistance gene. (A) Cells were harvested after 168 h and the cell lysates
were analyzed by immunoblotting using antibodies to Jab1, c-myc and
CDK2. (B) Cells were selected in the presence of G418 (1 mg/ml) for 2
weeks and stained in 0.4% crystal violet. (a) no plasmid; (b) a
Luciferase-siRNA vector; (c) Luciferase- and c-myc-siRNA vectors;
(d) Luciferase- and hJab1-siRNA vectors; and (e) c-myc- and hJab1-
siRNA vectors. (C) Only colonies with a diameter >1 mm were
enumerated. Data shown are means ± S.D. #P = 0.2662 and
*P = 0.0074.
5842 A. Fukumoto et al. / FEBS Letters 580 (2006) 5836–5844induction of apoptosis [38]. The transfection of the adequate
amount of siRNA speciﬁcally designed based on the human
c-myc sequence into MIA PaCa-2 cells only marginally re-
duced the level of intracellular c-myc protein (Fig. 6A, 2nd
lane) (a higher dose of c-myc RNAi resulted in growth sup-
pression), but it did counteract the upregulation induced by
hJab1-siRNA (Fig. 6A, 4th lane). Importantly, c-myc siRNA
did not aﬀect the level of Jab1 expression. Transfection of c-
myc siRNA did not substantially alter the number of colonies
in the colony formation assay (P = 0.2662). However, in a
cotransfection assay, c-myc siRNA signiﬁcantly increased the
eﬃciency of colony formation in the presence of hJab1-siRNA
(P = 0.0074), suggesting that c-myc knockdown, at least par-
tially, rescued growth inhibition mediated by Jab1 depletion.In a control experiment, we designed siRNA speciﬁc to
human cyclin E, and used it in the assay. The introduction
of cyclin E siRNA generated a substantially reduced number
of colonies in MIA PaCa-2 cells (60–70% of the control value).
Cotransfection of cyclin E-siRNA with hJab1-siRNA further
decreased the eﬃciency of colony formation (data not shown),
indicating that Jab1- and cyclin E-depletion synergistically
inhibited the growth of these cancer cells. Thus, the rescue of
growth inhibition mediated by Jab1 depletion is highly speciﬁc
to c-myc siRNA and the results also suggest that, at least in
part, c-myc upregulation in hJab1-siRNA-treated cells actively
participates in the induction of apoptotic cell death.4. Discussion
In our previous study, we observed overexpression of Jab1
in pancreatic cancer [6] but its physiological relevance re-
mained to be determined. In the present study, we showed that
depletion of Jab1 resulted in growth inhibition of pancreatic
cancer cell lines, suggesting that strong expression of Jab1
not only represents a prognostic marker for malignant trans-
formation but also contributes to cancer cell proliferation
and survival. Because Jab1 overexpression was reported in a
variety of human cancers [25–35] in addition to those of pan-
creatic origin, it is reasonable to assume that the results ob-
tained here in pancreatic cancer cell lines can be applied to
other types of cancers. In fact, Jab1 depletion resulted in
growth inhibition of other types of cancer cells, such as the
breast cancer cell line MCF7 and the cervical cancer cell line
HeLa. Thus, Jab1 overexpression plays a critical role in the
growth of various human cancers and Jab1 could be a novel
tool for making a prognosis and a novel target in the treatment
of cancer.
Following the knockout of CSN components in mice, we
and others observed an upregulation of p53 expression in dy-
ing embryonic cells [24,39], suggesting that CSN regulates cell
viability through p53. In fact, CSN3 (CSN) is located up-
stream of COP1 [40], which functions as an E3 ubiquitin ligase
for p53 [41]. The present study, however, shows that cancer
cells containing a functionally inactivated p53 or genetic aber-
rations at the p53 locus can still be inhibited in their prolifer-
ation/by speciﬁc depletion of the Jab1 protein. The result does
not necessarily exclude the possibility that the CSN-p53 signal-
ing pathway regulates mammalian cell viability, but at least
suggest that mammalian cells contain the p53-independent
pathway by which CSN (Jab1) controls mammalian cell
growth. Supporting this notion, the p53-null allele did not res-
cue the embryonic lethality caused by the knocking out of the
CSN components (CSN2 and CSN5/Jab1), although double
knockout mice survived a little longer than single knockout
animals [24].
In the present study, we found that depletion of Jab1 resulted
in an increase in the expression of c-myc and prevention of this
upregulation partially rescued cell viability, implying that c-
myc, at least in part, participates in the Jab1-mediated regula-
tion of cell viability. Because c-myc is known to be involved
in both p53-dependent and -independent cell death in a variety
of biological responses [38], this assumption seems reasonable.
However, given that the expression of dozens of proteins was
upregulated or downregulated in Jab1-siRNA-treated cells, it
A. Fukumoto et al. / FEBS Letters 580 (2006) 5836–5844 5843is more likely that an undiscovered Jab1 target plays a central
role in the Jab1-mediated regulation of cell proliferation and
survival. In the rescue assay, the Jab1 mutant containing a sin-
gle amino acid substitution within the JAMM domain (JAMM
mutant) did not recover growth inhibition, suggesting that pro-
tein (de)neddylation plays an important role. The only known
target of CSN-mediated deneddylation is the cullin subunit of
the ubiquitin ligase [14,15], but the amount of neddylated
Cul1 did not signiﬁcantly change in Jab1-siRNA-treated cells.
It is possible that, in a certain situation, CSN selectively per-
forms deneddylation among the diﬀerent cullin subunits (e.g.,
Cul1, Cul3, Cul4, etc., especially Cul4), or, alternatively, some
other JAMM domain-associated activity plays a critical role in
Jab1-mediated growth control. It may be worth pointing out
that the expression of Skp2 was downregulated in Jab1-siR-
NA-treated cells, consistent with the recent idea that CSN
may somehow regulate the stability of a subset of the F-box
adaptor protein [42]. Although a number of potential targets
of Jab1 (Jab1 interacting proteins) have been found [7,8], none
of them seem to be directly linked to the control of cancer cell
proliferation and survival. Finding such target molecules will
help us understand the intracellular signaling pathway leading
from Jab1/CSN to mammalian cell proliferation and survival,
and may provide a new prognostic tool and a novel way to treat
cancer.
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